What are FcRn inhibitor drugs?

FcRn inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Neonatal Fc receptor (FcRn)). 1 are currently marketed, with 2 more in clinical development.

What are the marketed FcRn inhibitor drugs?

Marketed FcRn inhibitor drugs include IV efgartigimod.

FcRn inhibitor

1 marketed 2 in Phase 3

This page covers all FcRn inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Neonatal Fc receptor (FcRn), FcRn (neonatal Fc receptor).

Targets

Neonatal Fc receptor (FcRn) · FcRn (neonatal Fc receptor)

Marketed (1)

IV efgartigimod · Rambam Health Care Campus · Immunology
Efgartigimod is an IgG Fc receptor inhibitor that reduces circulating immunoglobulin G (IgG) antibodies by blocking their recycling through the neonatal Fc receptor (FcRn).

Phase 3 pipeline (2)

ARGX-113 · argenx · Immunology
ARGX-113 is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.
Nipocalimab SC-LIV · Janssen Research & Development, LLC · Immunology
Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions.